Table 2.
Cox proportional hazards model for the outcome of uncontrolled hypertension in the entire cohort, females, males, non-Hispanic Black participants, non-Hispanic White participants, older adults and non-older adult patients, rural and urban residing patients, those with breast cancer, as well as those taking cancer medications
| HR (95% CI, P) |
||||||
|---|---|---|---|---|---|---|
| Outcome – uncontrolled HTN greater than or equal to 140/90 | PRAPARE risk tally score | time at risk (person-months) | Univariable | Model 1 | Model 2 | Model 3 |
| Events/Total a | ||||||
| All population (n = 318) | ||||||
| 102/318 | 0-4 (n = 105) | 2025 | Reference | Reference | Reference | Reference |
| 5+ (n = 213) | 1.78 (1.13-2.81, P = .013) | 1.75 (1.11-2.76, P = .017) | 1.80 (1.13-2.87, P = .014) | 1.77 (1.10-2.83, P = .018) | ||
| Female (n = 175) | ||||||
| 49/175 | 0-4 (n = 60) | 1112 | Reference | Reference | Reference | Reference |
| 5+ (n = 115) | 1.73 (0.93-3.24, P = .085) | 1.80 (0.96-3.38, P = .066) | 1.78 (0.91-3.50, P = .092) | 1.50 (0.76-2.98, P = .246) | ||
| Male (n = 143) | ||||||
| 53/143 | 0-4 (n = 45) | 913 | Reference | Reference | Reference | Reference |
| 5+ (n = 98) | 1.72 (0.88-3.36, P = .114) | 1.73 (0.88-3.38, P = .109) | 1.67 (0.84-3.31, P = .140) | 1.78 (0.89-3.55, P = .103) | ||
| Non-Hispanic Black participants (n = 132) | ||||||
| 46/132 | 0-4 (n = 29) | 822 | Reference | Reference | Reference | Reference |
| 5+ (n = 103) | 2.25 (0.88-5.73, P = .089) | 2.21 (0.87-5.64, P = .096) | 2.44 (0.92-6.44, P = .073) | 2.45 (0.92-6.52, P = .074) | ||
| Non-Hispanic White participants (n = 174) | ||||||
| 51/174 | 0-4 (n = 74) | 1114 | Reference | Reference | Reference | Reference |
| 5+ (n = 100) | 1.57 (0.88-2.77, P = .124) | 1.62 (0.89-2.95, P = .113) | 1.65 (0.88-3.11, P = .119) | 1.56 (0.82-2.96, P = .171) | ||
| Older adults (n = 178) | ||||||
| 62/178 | 0-4 (n = 59) | 1134 | Reference | Reference | Reference | Reference |
| 5+ (n = 119) | 1.69 (0.97-2.93, P = .064) | 1.73 (0.99-3.03, P = .054) | 1.81 (1.01-3.23, P = .046) | 1.77 (0.99-3.17, P = .054) | ||
| Non-older adults (n = 140) | ||||||
| 40/140 | 0-4 (n = 46) | 891 | Reference | Reference | Reference | Reference |
| 5+ (n = 94) | 2.22 (0.97-5.06, P = .058) | 2.22 (0.94-5.25, P = .070) | 2.23 (0.92-5.42, P = .075) | 1.88 (0.77-4.62, P = .168) | ||
| Rural (n = 58) | ||||||
| 21/58 | 0-4 (n = 27) | 351 | Reference | Reference | Reference | Reference |
| 5+ (n = 31) | 1.19 (0.48-2.98, P = .705) | 1.03 (0.40-2.63, P = .955) | 1.10 (0.33-3.63, P = .876) | 1.11 (0.33-3.78, P = .869) | ||
| Urban (n = 260) | ||||||
| 81/260 | 0-4 (n = 78) | 1674 | Reference | Reference | Reference | Reference |
| 5+ (n = 182) | 2.03 (1.18-3.46, P = .010) | 2.02 (1.18-3.46, P = .011) | 2.05 (1.18-3.56, P = .011) | 2.03 (1.16-3.54, P = .013n) | ||
| Breast cancer (n = 75) | ||||||
| 17/75 | 0-4 (n = 23) | 436 | Reference | Reference | Reference | Reference |
| 5+ (n = 52) | 0.87 (0.29-2.61, P = .809) | 0.76 (0.25-2.31, P = .634) | 1.17 (0.32-4.31, P = .814) | 1.07 (0.28-4.14, P = .924) | ||
| Cancer medications (n = 174) | ||||||
| 54/174 | 0-4 (n = 62) | 1151 | Reference | Reference | Reference | Reference |
| 5+ (n = 112) | 1.75 (0.95-3.23, P = .074) | 1.56 (0.83-2.91, P = .164) | 1.66 (0.88-3.16, P = .121) | 1.66 (0.87-3.18, P = .126) | ||
a
Based on the univariable analysis. PRAPARE = the Protocol for Responding to and Assessing Patients’ Assets, Risk, and Experiences; HR = hazards ratio; CI = confidence interval; HTN = hypertension.
Model 1: Adjusted for age and sex.
Model 2: Model 1 + diabetes mellitus, obesity, smoking status, alcohol drinking, chronic kidney disease, and obstructive sleep apnea.
Model 3: Model 2 + cancer metastasis and cancer treatment.